Bharat Immunological & Biologicals Corporation Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bharat Immunological & Biologicals Corporation Ltd. on BSE

Load latest

Bharat Immunological & Biologicals Corporation Ltd.

19 May 2020, 03:39PM

21.87

3.40%

Company Update

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Compliance Certificate Under Regulation 7(3) Of Securities …

BSE India

Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is submitted the Certificate duly signed by M/s MAS Services Ltd, Share Transfer Agent and the Company Secretary of Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) for the year ending on 31.03.2020 for information and record please.

pdf

Bharat Immunological & Biologicals Corporation Ltd.

29 Apr 2020

21.87

3.40%

Company Update

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Bharat Immunologicals & Biologicals Corporation Ltd reply to clarification sought by the exchange

BSE India

The Exchange had sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd with respect to "interview of CEO of the Company on NDTV 24x7 news channel, wherein he had mentioned that the company is in process of developing/ testing the vaccine for COVID 19." Source: NDTV 24x7 dated April 28, 2020.Bharat Immunologicals & Biologicals Corporation Ltd replied stating that "It is referred the email received from exchange and information is being provided that BIBCOL is not doing and research activity related to development of vaccine of Covid-19 and no official of BIBCOL has given any interview on NDTV or any other channel or media.Hence information under Regulation 30 of SEBI LODR 2015 may please be treated as NIL."

Bharat Immunological & Biologicals Corporation Ltd.

29 Apr 2020

21.87

3.40%

Company Update

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd

BSE India

The Exchange has sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd with respect to "interview of CEO of the Company on NDTV 24x7 news channel, wherein he had mentioned that the company is in process of developing/ testing the vaccine for COVID 19." Source: NDTV 24x7 dated April 28, 2020.The reply is awaited.

Bharat Immunological & Biologicals Corporation Ltd.

09 Apr 2020

21.87

3.40%

Company Update

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Shareholding for the Period Ended March 31, 2020

BSE India

Bharat Immunologicals & Biologicals Corporation Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here

Bharat Immunological & Biologicals Corporation Ltd.

09 Apr 2020

21.87

3.40%

Company Update

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Statement Of Investor Complaints For The Quarter Ended March 2020

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- SANDIP KUMAR LALDesignation :- Company Secretary and Compliance Officer

Bharat Immunological & Biologicals Corporation Ltd.

19 Feb 2020, 04:18PM

21.87

3.40%

Result

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Submission Of Limited Review Report Of The …

BSE India

In pursuance of Regulation 33(3) (C ) of the LODR with Stock Exchange, please find enclosed the Limited Review Report along with the financial results for the Quarter and nine months ended 31st December 2019.

pdf

Bharat Immunological & Biologicals Corporation Ltd.

31 Jan 2020

21.87

3.40%

Board Meeting

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Submission Of Unaudited Quarterly Financial Results For …

BSE India

In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter ended December 2019 approved by the Board of the Company in its Meeting on 31.01.2020. This submission of UAFR will succeeded by XBRL filing as per the requirement of Exchange. Submitted please.

pdf

Bharat Immunological & Biologicals Corporation Ltd.

23 Jan 2020

21.87

3.40%

Board Meeting

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Board Meeting Intimation for Intimation Of Date …

BSE India

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2020 ,inter alia, to consider and approve Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 31st January 2020, to approve and take on record the Un-audited Quarterly Financial Results of the Company for the quarter ended 31st December 2019.

pdf

Bharat Immunological & Biologicals Corporation Ltd.

13 Jan 2020

21.87

3.40%

Company Update

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Shareholding for the Period Ended December 31, 2019

BSE India

Bharat Immunologicals & Biologicals Corporation Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here

Bharat Immunological & Biologicals Corporation Ltd.

08 Jan 2020

21.87

3.40%

Company Update

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Statement Of Investor Complaints For The Quarter Ended December 2019

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- SANDIP KUMAR LALDesignation :- Company Secretary and Compliance Officer

No results found

Is Bharat Immunological & Biologicals Corporation Ltd. worth buying?

135 Votes:

Buy 69.63%

Sell 14.81%

Hold 15.56%

39.05% Fall from 52W High

Bharat Immunological & Biologicals Corporation Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bharat Immunological & Biologicals Corporation Ltd. on BSE